ClinicalTrials.gg
CompletedNCT04611802Updated Dec 21, 2023

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

A Phase 3 interventional study of SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period) and Placebo (Initial Vaccination Period) in SARS-CoV Infection and Covid19, sponsored by Novavax. Completed at 154 sites in 3 countries. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-21.

Sponsored by Novavax · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 7 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2023.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
33,000
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Severe Acute Respiratory Syndrome with a site in United States — 5 open to participants now, 6 under way, 2 of them phase 3. Severe Acute Respiratory Syndrome · United States.

Enrollment
2nd of 79
33,000 · median 100
Started
2020
with 60 others
Phase 3
27 of 106
1 open now
Registered
70th of 106
by date

Among the 106 studies in Severe Acute Respiratory Syndrome with a site in United States, this one is the 2nd largest by enrollment of the 79 interventional ones that give a count, is one of 61 that started in 2020, is one of 27 in phase 3, and was the 70th registered.

Severe Acute Respiratory Syndrome

376 studies on the registry are indexed under Severe Acute Respiratory Syndrome; 14 are open to participants now.

Browse Severe Acute Respiratory Syndrome studies →

Open to participants now

5 of the 106 studies in Severe Acute Respiratory Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Severe Acute Respiratory Syndrome studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Severe Acute Respiratory Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants and adolescent participants. Additionally providing a Booster Dose to fully vaccinated participants. A substudy is to be conducted at selected sites to evaluate the safety and immunogenicity of a fourth dose (second booster) of NVX-CoV2373 in adults and adolescents, previously fully vaccinated and subsequently boosted with a third dose (first booster)

Read the detailed description

This is a Phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of SARS-CoV-2 rS with Matrix-M1 adjuvant in adult participants ≥ 18 years of age (Adult Main Study) and adolescent participants 12 to \<18 years (Pediatric Expansion). Additionally, a Booster Amendment will allow for the evaluation of a booster dose of SARS-CoV-2 rS with Matrix-M1 adjuvant in participants who completed the primary series of active vaccine in the Adult Main Study or Pediatric Expansion, as well as in participants who previously completed the primary series of an authorized/approved COVID-19 vaccine. Additionally, a sub-study conducted at specific sites will allow for the evaluation of a second booster dose of SARS-CoV-2 rS with Matrix-M1 adjuvant in participants who completed the primary series of active vaccine in the Adult Main Study and Pediatric Expansion as well as a booster dose in the Booster Amendment of the study.

03

Conditions studied

  • SARS-CoV Infection
  • Covid19

Keywords

  • Coronavirus
  • Prevent-19
  • Booster
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult Participants :

Each participant in the Adult Main Study and/or the Booster Amendment must meet all of the following criteria to be enrolled in this study:

  1. Adults ≥ 18 years of age at screening who, by virtue of age, race, ethnicity or life circumstances, are considered at substantial risk of exposure to and infection with SARS CoV-2.
  2. Willing and able to give prior to study enrollment and to comply with study procedures.
  3. Participants of (defined as any participant who has experienced menarche and who is NOT surgically sterile [i.e., hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or [defined as amenorrhea at least 12 consecutive months]) must agree to be heterosexually inactive from at least 28 days prior to enrollment and through 3 months after the last vaccination OR agree to consistently use a medically acceptable method of from at least 28 days prior to enrollment and through 3 months after the last vaccination.
  4. Is medically stable, as determined by the investigator (based on review of health status, vital signs [to include body temperature], medical history, and targeted physical examination [to include body weight]). Vital signs must be within medically acceptable ranges prior to the first vaccination.
  5. Agree to not participate in any other SARS-CoV-2 prevention trial during the study follow-up.
  6. For the Booster Amendment only, active participants who received a full dose regimen of active vaccine (SARS-CoV-2 rS with Matrix-M1 adjuvant) or any authorized/approved COVID-19 vaccine are eligible for participation. Such participants must demonstrate receipt by producing valid documentation of vaccination at the booster visit.

Pediatric Participants :

Each participant in the Pediatric Expansion and/or the Booster Amendment must meet all of the following criteria to be enrolled in this study:

  1. Pediatric participants 12 to \< 18 years of age at screening, determined to be healthy or medically stable by the investigator (based on review of health status, vital signs [to include body temperature], medical history, and targeted physical examination [to include body weight]). Vital signs must be within medically acceptable ranges prior to the first vaccination.
  2. Participant and parent(s)/caregiver(s) or legally acceptable representative willing and able to give informed consent and assent, as required, prior to study enrollment and to comply with study procedures.
  3. Participants of childbearing potential (defined as any participant who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] must agree to be heterosexually inactive from at least 28 days prior to enrollment and through 3 months after the last vaccination OR agree to consistently use a medically acceptable method of contraception from at least 28 days prior to enrollment and through 3 months after the last vaccination.
  4. Agree to not participate in another SARS-CoV-2 prevention trial during the study follow-up.
  5. For the Booster Amendment only, active participants who received a full dose regimen of active vaccine (SARS-CoV-2 rS with Matrix-M1 adjuvant) or any authorized/approved COVID-19 vaccine are eligible for participation. Such participants must demonstrate receipt by producing valid documentation of vaccination.

Site-Specific Sub Study:

Each participant in the Substudy must meet all of the following criteria to be enrolled in this study:

  1. Be an active, enrolled participant in the 2019nCoV-301 study.
  2. Adults 18 years of age or older or adolescents 12 to \< 18 years of age at initial screening for the parent study.
  3. Willing and able to give informed consent prior to substudy enrollment and to comply with extra study procedures.
  4. Documented receipt of the 2 doses of the primary series of NVX-CoV2373 and the booster (third dose) of NVX-CoV2373 in the parent protocol. The booster dose must have been administered at least 6 months prior to entering the substudy.
  5. Participants of childbearing potential (defined as any participant who has experienced menarche and who is NOT surgically sterile or postmenopausal) must agree to be heterosexually inactive from at least 28 days prior to entering and through the end of the substudy OR agree to consistently use a medically acceptable method of contraception for the 28 days of follow-up for the substudy.
  6. Is medically stable, as determined by the investigator (based on review of health status, vital signs (to include body temperature) and targeted physical examination (if medically indicated by reported symptoms). Vital signs must be within medically acceptable ranges prior to administration of study vaccination.
  7. Agree to not participate in any other non-NVX-CoV2373 study during the substudy.

Note: For participants who develop COVID-19, anti-SARS-CoV-2 therapy (approved, authorized or ) is permitted.

Exclusion criteria

Exclusion Criteria:

Adult and adolescent participants meeting any of the following criteria will be excluded from the study:

  1. Unstable acute or chronic illness. Criteria for unstable medical conditions include:

    1. Substantive changes in chronic prescribed medication (change in class or significant change in dose) in the past 2 months.
    2. Currently undergoing workup of undiagnosed illness that could lead to diagnosis of a new condition.

    Note: Well-controlled [HIV] with undetectable HIV RNA [\< 50 copies/mL] and > 200 cells/µL for at least 1 year, documented within the last 6 months, is NOT considered an unstable chronic illness. Participant's or parent's/caregiver's verbal report will suffice as documentation.

  2. Participation in research involving an product (drug/biologic/device) administered within 45 days prior to first study vaccination.
  3. History of a previous laboratory-confirmed diagnosis of SARS-CoV-2 infection or COVID-19. A previous diagnosis of COVID-19 during participation in this trial is not exclusionary for the Booster Amendment.
  4. Received any vaccine within 4 days prior to first study vaccination or planned receipt of any vaccine before Day 49 (i.e., 28 days after second vaccination), except for influenza vaccination, which may be received ≥ 4 days prior to or ≥ 7 days after either study vaccination. Rabies vaccine, at any time it is medically indicated, is not exclusionary. Prior receipt of another approved or authorized COVID-19 vaccine prior to booster injection is not exclusionary in the Booster Amendment. Such participants must provide documentation of vaccine and date(s) of administration.
  5. or immunodeficiency disease/condition (iatrogenic or congenital) or therapy that causes . NOTE: Stable endocrine disorders (eg, thyroiditis, pancreatitis, including stable diabetes mellitus) are NOT excluded.
  6. Chronic administration (defined as > 14 continuous days) of immunosuppressant or systemic causing clinically significant immunocompromise, within 90 days prior to first study vaccination and/or third (booster) vaccination. NOTE: An immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 20 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids is permitted. Topical tacrolimus and ocular cyclosporin are permitted.
  7. Received immunoglobulin or blood-derived products, within 90 days prior to first study vaccination and/or third (booster) vaccination.
  8. Active cancer () on chemotherapy that is judged to cause clinically significant immunocompromise within 1 year prior to first study vaccination (with the exception of malignancy cured via excision, at the discretion of the investigator). This criterion is not applicable to participants diagnosed during participation in this trial who accept participation in the Booster Amendment.
  9. Any known allergies to products contained in the investigational product.
  10. Participants who are breastfeeding, pregnant, or who plan to become pregnant within 3 months following last study vaccination.
  11. Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the trial vaccine or interpretation of study results.
  12. Study team member or first-degree relative of any study team member (inclusive of Sponsor, and study site personnel involved in the study).
  13. Current participation in any other COVID-19 prevention clinical trial.
  14. Adult participants who have not received a full dose of any authorized/approved COVID-19 vaccine and are unable to provide valid documentation of vaccination will be excluded from the Booster Amendment.

Adult and adolescent participants meeting any of the following criteria will be excluded from the substudy:

  1. History of laboratory-confirmed (by PCR or other antigen testing) COVID-19 infection ≤ 4 months prior to entering the substudy.
  2. Known to be clinically significantly immunocompromised.
  3. Received immunoglobulin, blood-derived products, or immunosuppressant drugs within 90 days prior to entering substudy.
  4. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the end of substudy.
  5. History of confirmed myocarditis and/or pericarditis since enrollment to the parent study.
  6. Any condition that, in the opinion of the investigator, might pose a health risk to the participant, interfere with protocol compliance or interfere with evaluation of the trial vaccine.
  7. Study team member or immediate family member of any study team member (inclusive of Sponsor, CRO, and study site personnel involved in the conduct or planning of the substudy).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33,000 participants (actual)

Study arms

  • Experimental
    SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial vaccination)

    2 doses of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21 in Initial Vaccination Period.

    Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)

  • Placebo comparator
    Placebo (Initial Vaccination)

    2 doses of Placebo (Saline), 1 dose each on Days 0 and 21in Initial Vaccination Period.

    Other: Placebo (Initial Vaccination Period)

  • Experimental
    SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination)

    One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 or Day 21 in Crossover Vaccination Period.

    Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)

  • Experimental
    SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)

    One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 Booster Vaccination Period.

    Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)

  • Experimental
    SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster)

    One dose of 5 μg SARS-CoV-2 rS + 50 μg Matrix-M1 adjuvant (co-formulated) on Day 0 Second Booster Vaccination Period.

    Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)

  • Placebo comparator
    Placebo (Crossover Vaccination)

    One dose of Placebo (Saline) on Day 0 or Day 21 in Crossover Vaccination Period.

    Other: Placebo (Crossover Vaccination period)

Interventions

  • BiologicalSARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)

    Drug page: NVX-CoV2373 adjuvated lipid nanoparticle

    Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.

    Also known as: NVX-CoV2373

  • OtherPlacebo (Initial Vaccination Period)

    Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21 in Initial Vaccination Period.

    Also known as: Sodium chloride 0.9% (BP, sterile)

  • BiologicalSARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period)

    Drug page: NVX-CoV2373 adjuvated lipid nanoparticle

    In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0 or Day 21

    Also known as: NVX-CoV2373

  • OtherPlacebo (Crossover Vaccination period)

    In Crossover Vaccination period, one dose of intramuscular (deltoid) injection of placebo (0.5 mL) on Day 0 or Day 21

    Also known as: Sodium chloride 0.9% (BP, sterile)

  • BiologicalSARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination)

    Drug page: NVX-CoV2373 adjuvated lipid nanoparticle

    In Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0

    Also known as: NVX-CoV2373

  • BiologicalSARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)

    Drug page: NVX-CoV2373 adjuvated lipid nanoparticle

    In Second Booster Vaccination period, one dose of intramuscular (deltoid) injection of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Day 0

    Also known as: NVX-CoV2373

06

What researchers measure

Primary outcomes

  1. Adult Main Study and Pediatric Expansion: Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19)

    Number of participants with first occurrence of positive (+) polymerase chain reaction (PCR)-confirmed SARS-CoV-2 illness with symptomatic mild, moderate, or severe COVID-19, with each symptom lasting for at least 2 consecutive days, with onset from Day 28 (7 days after second vaccination dose) through the length of the study.

    Time frame: Day 28 to Day 750

  2. Pediatric Expansion: Reactogenicity Incidence and Severity

    Reactogenicity incidence and severity (mild, moderate or severe) recorded by all participants on their electronic patient-reported outcome diary application (eDiary) on days of vaccination and subsequent 6 days (total 7 days after each vaccine injection).

    Time frame: Day 0 to Day 27

  3. Pediatric Expansion: Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49

    Number of participants with mild, moderate, or severe MAAEs through Day 49 i.e. 28 days after second injection of each set of vaccinations (initial and crossover).

    Time frame: Day 0 to Day 49

  4. Pediatric Expansion: Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49

    Number of participants with mild, moderate, or severe AEs through Day 49 i.e. 28 days after second injection of each set of vaccinations (initial and crossover).

    Time frame: Day 0 to Day 49

  5. Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Specified Time Points

    Number of participants with mild, moderate, or severe MAAEs attributed to study vaccine through specified time points approximately every 3 and 6 months.

    Time frame: Day 90 to Day 750

  6. Pediatric Expansion: Incidence and Severity of Serious Adverse Events (SAEs) Through Specified Time Points

    Number of participants with mild, moderate, or severe SAEs attributed to study vaccine through specified time points approximately every 3 and 6 months.

    Time frame: Day 90 to Day 750

  7. Pediatric Expansion: Incidence and Severity of Adverse Events of Special Interest (AESIs) Through Specified Time Points

    Number of participants with mild, moderate, or severe AESIs attributed to study vaccine through specified time points approximately every 3 and 6 months.

    Time frame: Day 90 to Day 750

  8. Pediatric Expansion: Incidence and Severity of SAEs Attributed to Study Vaccine Through Specified Time Points until Month 24

    Number of participants with mild, moderate, or severe SAEs attributed to study vaccine and AESIs through specified time points until Month 24 or the EoS.

    Time frame: Day 90 to Day 750

  9. Pediatric Expansion: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Specified Time Points until Month 24

    Number of participants with mild, moderate, or severe MAAEs attributed to study vaccine and AESIs through specified time points until Month 24 or the EoS.

    Time frame: Day 90 to Day 750

  10. Pediatric Expansion: Incidence and Severity of AESIs Attributed to Study Vaccine Through Specified Time Points until Month 24

    Number of participants with mild, moderate, or severe AESIs attributed to study vaccine and AESIs through specified time points until Month 24 or the EoS.

    Time frame: Day 90 to Day 750

  11. Pediatric Expansion: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specified Time Points

    Number of participants with antibodies to SARS-CoV-2 NP at Day 35 to determine natural infection and to determine the incidence of asymptomatic infection acquired during study follow-up.

    Time frame: Day 35

  12. Pediatric Expansion: Deaths Due to Any Cause

    Number of participants who died during the study due to any cause.

    Time frame: Day 0 to Day 750

Secondary outcomes

  1. Adult Main Study and Pediatric Expansion: Participants with Symptomatic Moderate or Severe COVID-19

    Number of participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with symptomatic moderate or severe COVID-19, with each symptom lasting for at least 2 consecutive days, with onset from Day 28 (7 days after second vaccination dose) through the length of the study.

    Time frame: Day 28 to Day 750

  2. Adult Main Study and Pediatric Expansion: Participants with Any Symptomatic COVID-19

    Number of participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with any symptomatic COVID-19, with each symptom lasting for at least 2 consecutive days, with onset from Day 28 (7 days after second vaccination dose) through the length of the study.

    Time frame: Day 28 to Day 750

  3. Adult Main Study and Pediatric Expansion: Neutralizing Antibody Activity Expressed as Geometric Mean Titers (GMTs)

    Neutralizing antibody activity as detected by microneutralization assay (MN) as expressed as GMTs at Days 0, 35 and at specified time points through EoS.

    Time frame: Day 0 to Day 750

  4. Adult Main Study and Pediatric Expansion: Neutralizing Antibody Activity Expressed as Geometric Mean Fold Rises (GMFRs)

    Neutralizing antibody activity as detected by MN as expressed as GMFRs at Days 0, 35 and at specified time points through EoS.

    Time frame: Day 0 to Day 750

  5. Adult Main Study and Pediatric Expansion: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMTs

    Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMTs at Days 0, 35 and at specified time points through EoS.

    Time frame: Day 0 to Day 750

  6. Adult Main Study and Pediatric Expansion: Serum IgG Antibody Levels Expressed as GMFRs

    Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Days 0, 35 and at specified time points through EoS.

    Time frame: Day 0 to Day 750

  7. Adult Main Study and Pediatric Expansion: Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as GMTs

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMTs at Days 0, 35 and at specified time points through EoS.

    Time frame: Day 0 to Day 750

  8. Adult Main Study and Pediatric Expansion: hACE2 Receptor Binding Inhibition Assay Expressed as GMFRs

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMFRs at Days 0, 35 and at specified time points through EoS.

    Time frame: Day 0 to Day 750

  9. Adult Main Study and Pediatric Expansion: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMTs at Later Time Points

    Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs at Months 6, 12, 18, and 24.

    Time frame: Day 165 to Day 750

  10. Adult Main Study and Pediatric Expansion: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMFRs at Later Time Points

    Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Months 6, 12, 18, and 24.

    Time frame: Day 165 to Day 750

  11. Adult Main Study and Pediatric Expansion: hACE2 Receptor Binding Inhibition Assay Expressed as GMTs at Later Time Points

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMTs at Months 6, 12, 18, and 24.

    Time frame: Day 165 to Day 750

  12. Adult Main Study and Pediatric Expansion: hACE2 Receptor Binding Inhibition Assay Expressed as GMFRs at Later Time Points

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMFRs at Months 6, 12, 18, and 24.

    Time frame: Day 165 to Day 750

  13. Adult Main Study and Pediatric Expansion: Neutralizing Antibody Activity Expressed as GMTs at Later Time Points

    Neutralizing antibody activity as detected by MN as expressed as GMTs at Months 6, 12, 18, and 24.

    Time frame: Day 165 to Day 750

  14. Adult Main Study and Pediatric Expansion: Neutralizing Antibody Activity Expressed as GMFRs at Later Time Points

    Neutralizing antibody activity as detected by MN as expressed as GMFRs at Months 6, 12, 18, and 24.

    Time frame: Day 165 to Day 750

  15. Adult Main Study and Pediatric Expansion: Description of Course, Treatment and Severity of COVID-19

    Description of course, treatment and severity of COVID-19 reported after a PCR-confirmed case via the Endpoint Form.

    Time frame: Day 28 to Day 750

  16. Adult Main Study: Reactogenicity Incidence and Severity

    Reactogenicity incidence and severity (mild, moderate or severe) recorded by all participants on their electronic patient-reported outcome diary application (eDiary) on days of vaccination and subsequent 6 days (total 7 days after each vaccine injection).

    Time frame: Day 0 to Day 27

  17. Adult Main Study: Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49

    Number of participants with mild, moderate, or severe MAAEs through Day 49 i.e. 28 days after second injection of each set of vaccinations (initial and crossover).

    Time frame: Day 0 to Day 49

  18. Adult Main Study: Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49

    Number of participants with mild, moderate, or severe AEs through Day 49 i.e. 28 days after second injection of each set of vaccinations (initial and crossover).

    Time frame: Day 0 to Day 49

  19. Adult Main Study: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Specified Time Points

    Number of participants with mild, moderate, or severe MAAEs attributed to study vaccine through specified time points approximately every 3 months.

    Time frame: Day 90 to Day 750

  20. Adult Main Study: Incidence and Severity of Serious Adverse Events (SAEs) Attributed to Study Vaccine Through Specified Time Points

    Number of participants with mild, moderate, or severe SAEs attributed to study vaccine through specified time points approximately every 3 months.

    Time frame: Day 90 to Day 750

  21. Adult Main Study: Incidence and Severity of Adverse Events of Special Interest (AESIs) Attributed to Study Vaccine Through Specified Time Points

    Number of participants with mild, moderate, or severe AESIs attributed to study vaccine through specified time points approximately every 3 months.

    Time frame: Day 90 to Day 750

  22. Adult Main Study: Incidence and Severity of SAEs Attributed to Study Vaccine Through Specified Time Points until Month 24

    Number of participants with mild, moderate, or severe SAEs attributed to study vaccine and AESIs through specified time points until Month 24 or the EoS.

    Time frame: Day 90 to Day 750

  23. Adult Main Study: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Specified Time Points until Month 24

    Number of participants with mild, moderate, or severe MAAEs attributed to study vaccine and AESIs through specified time points until Month 24 or the EoS.

    Time frame: Day 360 to Day 750

  24. Adult Main Study: Incidence and Severity of AESIs Attributed to Study Vaccine Through Specified Time Points until Month 24

    Number of participants with mild, moderate, or severe AESIs attributed to study vaccine and AESIs through specified time points until Month 24 or the EoS.

    Time frame: Day 360 to Day 750

  25. Adult Main Study and Pediatric Expansion: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specified Time Points

    Number of participants with antibodies to SARS-CoV-2 NP at Days 0 and 35, or at specified time points through EoS to determine natural infection and to determine the incidence of asymptomatic infection acquired during study follow-up.

    Time frame: Day 0 to Day 750

  26. Adult Main Study and Pediatric Expansion: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Any Time Point

    Number of participants with antibodies to SARS-CoV-2 NP, regardless of whether the infection was symptomatic.

    Time frame: Day 0 to Day 750

  27. Adult Main Study: IgG antibodies to SARS-CoV-2 rS at Day 35 After First Crossover Vaccination

    The ratio of geometric mean IgG antibody concentrations will be computed at Day 35 for the new manufacturing process versus the old manufacturing process using the data collected from 300 active vaccine recipients 18 to ≤ 64 years of age enrolled at selected study sites.

    Time frame: Day 35 after the first crossover vaccination

  28. Adult Main Study : Deaths Due to Any Cause

    Number of participants who died during the study due to any cause.

    Time frame: Day 0 to Day 750

  29. Adult Main Study and Pediatric Expansion: Participants with 1st episode of positive Polymerase Chain Reaction (PCR) for Coronavirus Disease 2019 (COVID-19) due to a variant not considered as a "variant of concern/interest"

    Number of participants with first episode of PCR-positive COVID-19, as defined under the primary endpoint, shown by gene sequencing to represent a variant not considered as a "variant of concern/interest" according to the CDC Variants Classification.

    Time frame: Day 28 to Day 750

Other outcomes

  1. Booster Amendment: Participants with symptomatic mild, moderate or severe COVID-19

    First episode of PCR-positive mild, moderate, or severe COVID-19 occurring ≥ 7 days after the third (booster) vaccine dose.

    Time frame: Day 0 to Day 7

  2. Booster Amendment: Participants with PCR positive moderate-to-severe COVID-19

    First episode of PCR-positive moderate-to-severe COVID-19 occurring ≥ 7 days after the third (booster) vaccine dose.

    Time frame: Day 0 to Day 7

  3. Booster Amendment: Participants with PCR positive COVID-19 due to a variant not considered "variant of interest/concern"

    First episode of PCR-positive COVID-19 occurring ≥7 days after the third (booster) vaccine dose and shown by gene sequencing to represent a variant not considered as a "variant of concern/interest" according to the CDC Variants Classification

    Time frame: Day 0 to Day 7

  4. Booster Amendment: Participants with PCR positive COVID-19 due to a 'variant of concern/interest"

    First episode of PCR-positive COVID-19 occurring ≥7 days after the third (booster) vaccine dose, and shown by gene sequencing to represent a "variant of concern/interest" according to the CDC Variants Classification.

    Time frame: Day 0 to Day 7

  5. Booster Amendment: Neutralizing antibody activity expressed as GMT

    Neutralizing antibody titers from Immunogenicity Population immediately prior and at 28 days after administration of the third (booster) vaccine dose expressed as GMT.

    Time frame: Day 0 to Day 28

  6. Booster Amendment: Neutralizing antibody activity expressed as GMFR

    Neutralizing antibody titers from Immunogenicity Population immediately prior and at 28 days after administration of the third (booster) vaccine dose expressed as GMFR.

    Time frame: Day 0 to Day 28

  7. Booster Amendment: Serum IgG antibody levels expressed as GMT

    Serum levels of IgG to SARS-CoV-2 S protein from Immunogenicity Population immediately prior and at 28 days after administration of the third (booster) vaccine dose expressed as GMT.

    Time frame: Day 0 to Day 28

  8. Booster Amendment: Serum IgG antibody levels expressed as GMFR

    Serum levels of IgG to SARS-CoV-2 S protein from Immunogenicity Population immediately prior and at 28 days after administration of the third (booster) vaccine dose expressed as GMFR.

    Time frame: Day 0 to Day 28

  9. Booster Amendment: hACE2 receptor binding inhibition assay expressed as GMT

    hACE2 inhibition titers from Immunogenicity Population immediately prior and at 28 days after administration of the third (booster) vaccine dose expressed as GMT.

    Time frame: Day 0 to Day 28

  10. Booster Amendment: hACE2 receptor binding inhibition assay expressed as GMFR

    hACE2 inhibition titers from Immunogenicity Population immediately prior and at 28 days after administration of the third (booster) vaccine dose expressed as GMFR.

    Time frame: Day 0 to Day 28

  11. Booster Amendment: Incidence and severity of unsolicited AE's

    Incidence and severity of unsolicited AEs through 28 days after the third (booster) vaccine dose.

    Time frame: Day 0 to Day 28

  12. Booster Amendment: Incidence and severity of MAAE's, SAE's and AESI's

    Incidence and severity of MAAEs attributed to study vaccine, SAEs and AESIs through EoS.

    Time frame: Day 0 to Day 720

  13. Booster Amendment: Description of course, treatment and severity of COVID-19

    Description of course, treatment and severity of COVID-19 reported after a PCR-confirmed case occurring ≥7 days after the third (booster) vaccine dose via the Endpoint Form.

    Time frame: Day 0 to Day 7

  14. Booster Amendment: Reactogenicity Incidence and Severity

    Reactogenicity incidence and severity (mild, moderate or severe) recorded by all participants on their electronic patient-reported outcome diary application (eDiary) on days of the third (booster) vaccination and subsequent 6 days.

    Time frame: Day0 to Day 7

  15. Booster Amendment: Deaths Due to Any Cause

    Number of participants who died during the study due to any cause.

    Time frame: Day 0 to Day 720

  16. Site Specific Sub Study: Serum IgG to the SARS-CoV-2 spike protein expressed as GMEU

    IgG geometric mean ELISA unit concentrations (EU/ml) to the SARS-CoV-2 spike protein at Day 28 following the second booster dose.

    Time frame: Day 28

  17. Site Specific Sub Study: Serum IgG antibody expressed as GMFR

    IgG Geometric Mean Fold Rises (GMFR) at Day 28 post second booster dose relative to Day 28 post-first booster dose.

    Time frame: Day 28

  18. Site Specific Sub Study: Serum IgG to the SARS-CoV-2 spike protein expressed as SPR

    Proportion of participants who achieve seroresponse (≥ 4-fold increase from pre-second booster baseline) in IgG ELISA unit concentrations to the SARS-CoV-2 spike protein at Day 28 post second booster dose.

    Time frame: Day 28

  19. Site Specific Sub Study: hACE2 Receptor Binding Inhibition Assay Expressed as GMTs

    hACE2 inhibition assay titers (GMTs) at Day 28 post second booster dose.

    Time frame: Day 28

  20. Site Specific Sub Study: hACE2 Receptor Binding Inhibition Assay Expressed as GMFR

    hACE2 GMFR at Day 28 post second booster dose relative to Day 28 post-first booster dose.

    Time frame: Day 28

  21. Site Specific Sub Study: hACE2 Receptor Binding Inhibition Assay Expressed as SPR

    Proportion of participants who achieve seroresponse (≥ 4-fold increase from pre-second booster baseline) in hACE2 inhibition assay titers at Day 28 post-second booster dose.Incidence, severity, and duration of solicited adverse events for the 7 days period following the second booster dose.

    Time frame: Day 28

  22. Site Specific Sub Study: Microneutralization assay (MN) titers to the SARS-CoV-2 wild type virus expressed as GMTs

    MN50 geometric mean titers to the SARS-CoV-2 wild-type virus at Day 28 post second booster dose.

    Time frame: Day 28

  23. Site Specific Sub Study: Microneutralization assay (MN) titers to the SARS-CoV-2 wild type virus expressed as GMFR

    MN50 GMFR at Day 28 post second booster dose relative to Day 28 post-first booster dose.

    Time frame: Day 28

  24. Site Specific Sub Study: Microneutralization assay (MN) titers to the SARS-CoV-2 wild type virus expressed as SPR

    Proportion of participants who achieve seroresponse (≥ 4-fold increase from pre-second booster baseline) in MN50 titers concentrations to the wild-type virus at Day 28 post second booster dose.

    Time frame: Day 28

07

Study locations

154 sites
  • Alabama Clinical Therapeutics, Llc (Pediatric Site)
    Birmingham, Alabama 35205, United States
  • Accel Research Sites (Adult Site)
    Birmingham, Alabama 35216, United States
  • Central Research Associates, Inc (Pediatric Site)
    Birmingham, Alabama 35242, United States
  • The Pain Center of Arizona (Adult Site)
    Phoenix, Arizona 85018, United States
  • Foothills Research Center-CCT Research (Pediatric Site)
    Phoenix, Arizona 85044, United States
  • Alliance for Multispecialty Research, LLC (Adult Site)
    Tempe, Arizona 85281, United States
  • Lynn Institute of the Ozarks (Adult Site)
    Little Rock, Arkansas 72204, United States
  • Preferred Research Partners, Inc. (Adult Site)
    Little Rock, Arkansas 72211, United States
  • Anaheim Clinical Trials (Adult Site)
    Anaheim, California 92801, United States
  • Advanced Clinical Research - Rancho Paseo (Pediatric & Adult Site)
    Banning, California 92220, United States
  • Coast Clinical Research, LLC (Pediatric Site)
    Bellflower, California 90706, United States
  • Velocity Clinical Research (Pediatric & Adult Site)
    Chula Vista, California 91911, United States
  • Premier Health Research Center, Llc (Pediatric Site)
    Downey, California 90240, United States
  • eStudySite - Corporate Offices (Adult Site)
    La Mesa, California 91942, United States
  • Paradigm Clinical Research Centers, Inc (Pediatric Site)
    La Mesa, California 92117, United States
  • WR-PRI, LLC (Adult Site)
    Los Alamitos, California 90720, United States
  • National Research Institute (Pediatric & Adult Site)
    Los Angeles, California 90057, United States
  • Orange County Research Institute (Pediatric Site)
    Ontario, California 91762, United States
  • Empire Clinical Research (Pediatric & Adult Site)
    Pomona, California 91767, United States
  • University of California Davis Health (Pediatric & Adult Site)
    Sacramento, California 95817, United States
  • Benchmark Research (Pediatric & Adult Site)
    Sacramento, California 95864, United States
  • California Research Foundation (Pediatric & Adult Site)
    San Diego, California 92123, United States
  • Synexus Clinical Research US, Inc. (Adult Site)
    Vista, California 92083, United States
  • Dignity Health Medical Foundation - Woodland (Adult Site)
    Woodland, California 95695, United States
  • University of Colorado Clinical and Translational Research Centers (Pediatric & Adult Site)
    Aurora, Colorado 80045, United States
  • Lynn Institute of the Rockies (Adult Site)
    Colorado Springs, Colorado 80918, United States
  • Meridian Clinical Research (Pediatric Site)
    Washington, District of Columbia 20016, United States
  • Howard University Hospital Howard/ University College of Medicine (Adult Site)
    Washington, District of Columbia 20060, United States
  • University Clinical Research-Deland, LLC dba Accel Research Sites (Pediatric & Adult Site)
    DeLand, Florida 32720, United States
  • SIMED Health, LLC / SIMED Research (Adult Site)
    Gainesville, Florida 32607, United States
  • M D Clinical (Adult Site)
    Hallandale Beach, Florida 33009, United States
  • Jacksonville Center for Clinical Research (Pediatric & Adult Site)
    Jacksonville, Florida 32216, United States
  • Meridien Research/Accel Research (Pediatric & Adult site)
    Lakeland, Florida 33803, United States
  • Miami Veterans Affairs Medical Center (Adult Site)
    Miami, Florida 33125, United States
  • Suncoast Research Associates, LLC (Adult Site)
    Miami, Florida 33135, United States
  • Acevedo Clinical Research Associates (Pediatric Site)
    Miami, Florida 33142, United States
  • Suncoast Research Associates, LLC (Adult Site)
    Miami, Florida 33173, United States
  • Clinical Neuroscience Solutions Inc (Pediatric & Adult Site)
    Orlando, Florida 32806, United States
  • Headlands Research Orlando (Adult Site)
    Orlando, Florida 32819, United States
  • Synexus Clinical Research US, Inc (Adult Site)
    Pinellas Park, Florida 33781, United States
  • Asclepes Research Centers (Adult & Pediatric Site)
    Spring Hill, Florida 34609, United States
  • Tampa Heart & Cardiovascular Center (Adult Site)
    Tampa, Florida 33607, United States
  • Office Of John S. Curran MD (Adult Site)
    Tampa, Florida 33612, United States
  • Synexus Clinical Research US, Inc. (Adult Site)
    The Villages, Florida 32162, United States
  • Comprehensive Clinical Trials, Llc (Pediatric & Adult site)
    West Palm Beach, Florida 33409, United States
  • Emory University Hospital (Adult Site)
    Atlanta, Georgia 30303, United States
  • Atlanta - Morehouse School of Medicine (Adult Site)
    Atlanta, Georgia 30310-1495, United States
  • Synexus Clinical Research US, Inc. (Adult Site)
    Atlanta, Georgia 30328, United States
  • Atlanta Center for Medical Research (Adult Site)
    Atlanta, Georgia 30331, United States
  • Tekton Research, Inc. (Pediatric Site)
    Chamblee, Georgia 30341, United States
  • Columbus Regional Research Institute (Adult Site)
    Columbus, Georgia 31904, United States
  • Clinical Research Atlanta (Adult Site)
    Stockbridge, Georgia 30281, United States
  • Advanced Clinical Research (Pediatric & Adult Site)
    Meridian, Idaho 83642, United States
  • Synexus Clinical Research US, Inc (Adult Site)
    Chicago, Illinois 60602, United States
  • Cedar Crosse Research Center (Adult Site)
    Chicago, Illinois 60607, United States
  • Providea Health Partners LLC (Adult Site)
    Evergreen Park, Illinois 60805, United States
  • Synexus USA (Adult Site)
    Evansville, Indiana 47714, United States
  • Buynak Clinical Research, P.C. (Pediatric & Adult Site)
    Valparaiso, Indiana 46383, United States
  • The University of Iowa Hospitals & Clinics (Adult Site)
    Iowa City, Iowa 52242, United States
  • Meridian Clinical Research (Adult Site)
    Sioux City, Iowa 51106, United States
  • Johnson County Clin-Trials, Inc. (Pediatric & Adult Site)
    Lenexa, Kansas 66219, United States
  • Alliance for Multispecialty Research (AMR) (Pediatric Site)
    Newton, Kansas 67114, United States
  • AMR Wichita East (Formerly Heartland Research Associates) (Pediatric SIte)
    Wichita, Kansas 67207, United States
  • Kentucky Pediatric/Adult Research (Pediatric Site)
    Bardstown, Kentucky 40004, United States
  • Brownsboro Park Pediatrics (Pediatric Site)
    Louisville, Kentucky 40207, United States
  • Meridian Clinical Research Baton Rouge (Pediatric Site)
    Baton Rouge, Louisiana 70809, United States
  • Meridian Clinical Research, LLC (Adult Site)
    Baton Rouge, Louisiana 70809, United States
  • Med Pharmics, LLC (Pediatric & Adult Site)
    Metairie, Louisiana 70006, United States
  • Willis-Knighton Physician Network (Adult Site)
    Shreveport, Louisiana 71101, United States
  • c/o The Pediatric Center of Frederick LLC (Adult & Pediatric Site)
    Baltimore, Maryland 21201, United States
  • Beth Israel Deaconess Medical Center (Adult Site)
    Boston, Massachusetts 02215, United States
  • VA Ann Arbor Healthcare System (Adult Site)
    Ann Arbor, Michigan 48105, United States
  • Wayne State University/ Children's Hospital of Michigan (Adult Site)
    Detroit, Michigan 48201, United States
  • University of Minnesota (Adult Site)
    Minneapolis, Minnesota 55455, United States
  • Synexus Clinical Research US, Inc. (Adult Site)
    Richfield, Minnesota 55423, United States
  • MedPharmics, LLC-Biloxi (Pediatric & Adult Site)
    Gulfport, Mississippi 39503, United States
  • The Curators of University of Missouri (Adult Site)
    Columbia, Missouri 65212, United States
  • Sundance Clinical Research, LLC (Pediatric & Adult Site)
    Saint Louis, Missouri 63141, United States
  • Meridian Clinical Research (Adult & Pediatric Site)
    Norfolk, Nebraska 68701, United States
  • Meridian Clinical Research Associates, LLC (Pediatric & Adult Site)
    Omaha, Nebraska 68134, United States
  • University Of Nebraska Medical Center (Pediatric & Adult Site)
    Omaha, Nebraska 68198, United States
  • Synexus Clinical Research US, Inc. (Adult Site)
    Henderson, Nevada 89052, United States
  • Clinical Research Center of Nevada (Pediatric Site)
    Las Vegas, Nevada 89014, United States
  • Clinical Research Consortium (Adult Site)
    Las Vegas, Nevada 89119, United States
  • Meridian Clinical Research (Pediatric Site)
    Binghamton, New York 13901, United States
  • Stony Brook Responder Vaccine Program (Adult Site)
    Commack, New York 11725, United States
  • Weill Cornell Chelsea CRS (Adult Site)
    New York, New York 10010, United States
  • Rochester Clinical Research (Pediatric & Adult Site)
    Rochester, New York 14609, United States
  • NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill (Pediatric & Adult Site)
    Chapel Hill, North Carolina 27514-7064, United States
  • The Charlotte-Mecklenburg Hospital Authority d/b/a Atrium Health (Pediatric & Adult Site)
    Charlotte, North Carolina 28207, United States
  • M3-Emerging Medical Research, LLC (Pediatric & Adult Site)
    Durham, North Carolina 27704, United States
  • Carolina Institute for Clinical Research (Adult Site)
    Fayetteville, North Carolina 28303, United States
  • Carolina Institute for Clinical Research (Adult Site)
    Fayetteville, North Carolina 28304, United States
  • Womack Army Medical Center (Adult Site)
    Fort Bragg, North Carolina 28310, United States
  • M3 Wake Research, Inc (Adult Site)
    Raleigh, North Carolina 27612, United States
  • PMG Research of Rocky Mount, LLC (Adult Site)
    Rocky Mount, North Carolina 27804, United States
  • Wake Forest Health Network - Pediatrics - Ford, Simpson, Lively & Rice (Pediatric Site)
    Salem, North Carolina 27103, United States
  • PMG Research of Wilmington, LLC (Adult Site)
    Wilmington, North Carolina 28401, United States
  • Synexus Clinical Research, US, Inc. (Adult Site)
    Akron, Ohio 44311, United States
  • Sterling Research Group, Ltd. (Adult Site)
    Cincinnati, Ohio 45219, United States

Showing the first 100 of 154 sites across 3 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Anez G, Dunkle LM, Gay CL, Kotloff KL, Adelglass JM, Essink B, Campbell JD, Cloney-Clark S, Zhu M, Plested JS, Roychoudhury P, Greninger AL, Patel N, McGarry A, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301 - Pediatric Expansion Study Group. Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial. medRxiv [Preprint]. 2022 Sep 21:2022.09.20.22279903. doi: 10.1101/2022.09.20.22279903. PubMed 36172135 ↗
  • Dunkle LM, Kotloff KL, Gay CL, Anez G, Adelglass JM, Barrat Hernandez AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruiz-Palacios GM, Corey L, Neuzil KM, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301 Study Group. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med. 2022 Feb 10;386(6):531-543. doi: 10.1056/NEJMoa2116185. Epub 2021 Dec 15. PubMed 34910859 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Apr 2023, 27 months.

Of 42 phase 3 interventional studies under Severe Acute Respiratory Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 27 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2020
First posted
Nov 2, 2020
StartActual
Dec 27, 2020
Primary completionActual
Apr 10, 2023
CompletionActual
Dec 15, 2023
Results delay requested
Jul 21, 2023
Last update
Dec 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04611802
Lead sponsor
Novavax
Collaborators
Department of Health and Human Services
Responsible party
Sponsor
First posted
Nov 2, 2020
Start date
Dec 27, 2020
Primary completion
Apr 10, 2023
Completion
Dec 15, 2023
Last update
Dec 21, 2023

Study contacts

Clinical Development
study director · Novavax, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle

Start the discussion